<DOC>
	<DOCNO>NCT00358397</DOCNO>
	<brief_summary>This study include one time intravenous ( IV ) infusion Clostridium novyi-NT ( C. novyi-NT ) spores treat solid tumor respond standard therapy .</brief_summary>
	<brief_title>One Time Injection Bacteria Treat Solid Tumors That Have Not Responded Standard Therapy</brief_title>
	<detailed_description>Investigators SKCCC develop bacterial strain ( C. novyi-NT ) infect tumor destroy , grow normal tissue . In animal experiment , single intravenous injection bacteria cause dramatic regression many tumor , tumor recur approximately ( ~ ) 30 % animal . This phase I dose escalation study use single dose Clostridium novyi-NT spore patient treatment-refractory solid tumor malignancy . The overall objective study determine safety document preliminary evidence anti-tumor activity patient population .</detailed_description>
	<criteria>Inclusion Criteria 1 . Histologically cytologically proven solid tumor malignancy proven referral CT scan chest , abdomen pelvis . 2 . Patients must refractory standard chemotherapy standard treatment exist . At least four week must elapse since completion prior chemotherapy . 3 . Patients must measurable disease ; define least one lesion whose long diameter accurately measure &gt; 2 cm . 4 . ECOG performance status 0 1 . 5 . Prior locoregional therapy , include cryotherapy , radiofrequency ablation , regional chemotherapy allow least 6 week elapse . 6 . Prior radiation therapy allow . At least 6 week must elapse since completion radiation therapy patient must recover side effect . 7 . Prior systemic radionuclide therapy allow . At least 4 week must elapse since completion therapy . 8 . Prior surgery allow . At least 6 week must elapse since completion major surgery patient must fully recover surgery attendant postsurgical complication . 9 . Patients must 18 year age old 10 . Patients childbearing potential must use adequate birth control measure ( e.g. , abstinence , barrier method spermicide ; use partner oral contraceptive , intrauterine device , implantable injectable contraceptive [ i.e. , Norplant DepoProvera ] surgical sterilization ) duration study continue precaution 12 month receive treatment . 11 . Screening physical exam must obtain less 7 day prior treatment result must meet following criterion : 1 . Temperature range : &lt; 38.0 great &gt; 36.0 2 . Respiratory rate : 1020 breath per minute 3 . Heart rate : 50 85 beat per minute 4 . Blood pressure : Systolic blood pressure great 90 mm Hg le 155 mm Hg 5 . % oxygen saturation pulse oximetry : &gt; 93 % 12 . Screening laboratory test obtain less 7 day prior treatment result must meet following criterion : 1 . WBC &gt; 3500/ mm3 /or ANC &gt; 1500/ mm3 , Platelet count 100,000/ mm3 . 2 . Serum creatinine &lt; 1.5X upper limit normal ( ULN ) . 3 . AST ALT &lt; 2.5X ULN , Alkaline phosphatase &lt; 2.5X ULN , Bilirubin &lt; 1.5X ULN . 4 . INR &lt; 1.3 5 . Hemoglobin &gt; 10.0 g/dL 13 . Negative serum pregnancy test female childbearing potential . 14 . The patient must capable give informed consent consent must obtain prior screen procedure consider standard procedure patient population . 15 . A baseline transthoracic echocardiogram demonstrating leave ventricular ejection fraction ( LVEF ) great 50 % significant valvular disease ( Subjects trace mild valvular stenosis regurgitation permit enroll study ) . 16 . Patient able stay within 45 minute drive time Johns Hopkins Hospital 28 day follow spore injection 7 day inpatient hospitalization period . 17 . Patient able stay within 45 minute drive time Johns Hopkins Hospital least 35 day recovery adverse event . Exclusion Criteria 1 . Weight &gt; 135 kg 2 . Chronic renal failure require hemodialysis peritoneal dialysis 3 . Patients renal cyst . 4 . Tumor lesion accessible percutaneous drainage . 5 . Any single contiguous lesion great &gt; 12.5 cm ( large diameter ) . 6 . The sum large crosssectional diameter number noncontiguous lesion &gt; 2 cm &gt; 25 cm . 7 . Use investigational drug within 30 day prior screen within 5 halflives investigational agent , whichever longer . 8 . Any documented evidence primary brain malignancy brain metastases 9 . Patients clinically significant ascites portosystemic hypertension , chronic jaundice cirrhosis . 10 . Patients indwell intrahepatic arterial pump 11 . Patients prosthetic joint , prosthetic valve , pacemaker implant foreign material . ( nonCNS surgical clip staple exclude ) 12 . Patients clinically significant pleural effusion 13 . Patients evidence hemodynamic compromise pericardial effusion , circumferential pericardial effusion , effusion great 1.0 cm location around heart . 14 . Documented cirrhosis liver clinical scenario encompass radiographic , clinical laboratory result 15 . Ongoing treatment immunosuppressive agent ( ) 16 . Any evidence serious infection ( pneumonia pyelonephritis ) history chronic recurrent infectious disease previous 3 month . Less serious infection ( acute upper respiratory tract infection ( cold ) simple urinary tract infection ) include upon discretion investigator . 17 . Patients opportunistic infection , include limited evidence active cytomegalovirus , Tuberculosis , active Pneumocystis carinii , Aspergillosis , histoplasmosis , atypical mycobacterium infection , within previous 6 month . 18 . Documented HIV infection . 19 . Active chronic Hepatitis B Hepatitis C. 20 . Presence transplant solid organ ( exception corneal transplant &gt; 3 month prior screen ) . 21 . History autoimmune disorder ( eg , systemic lupus , pemphigus vulgaris , myasthenia gravis ) ) , require medication . 22 . History Diabetes Mellitus ( type I II ) 23 . History rheumatic fever , endocarditis , great mild valvular disease . 24 . Patients depend upon COX II inhibitor NSAIDS 25 . History ongoing active arterial vasculopathy ( i.e . coronary artery disease , vasculitis , diabetic vasculopathy [ i.e . retinopathy , nephropathy , etc . ] ) evidence end organ damage ( visual loss , azotemia , cutaneous ulceration ) . 26 . History ischemic insult previous 12 month ( myocardial infarction , cerebrum vascular accident , ischemic tissue injury peripheral vascular disease ) 27 . History venous lymphatic stasis result venous stasis ulcer great 2+ edema lymphedema . 28 . History significant medical illness deem principal investigator subinvestigators unsuitable trial example : 1 . Symptomatic congestive heart failure 2 . Psychiatric Illness/Social Situation may make study dangerous 3 . Unstable angina pectoris 29 . History splenectomy 30 . Patients document Penicillin Metronidazole allergy 31 . Patients document allergy radiology contrast dye . 32 . Patient active diverticulitis 33 . Patient active dental abscesses 34 . Patients inflammatory bowel disease ( IBD ) 35 . Women pregnant , lactate breast feed 36 . Patients angiosarcoma 37 . Patients history positive PPD , past TB infection past atypical mycobacterium infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Clostridial</keyword>
	<keyword>Spore-forming bacteria</keyword>
	<keyword>hypoxia</keyword>
	<keyword>anaerobe</keyword>
	<keyword>Clostridium novyi</keyword>
	<keyword>Bacteria</keyword>
	<keyword>Bacteriolytic</keyword>
	<keyword>Tumor lysis</keyword>
	<keyword>Necrosis</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Bladder Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Experimental Therapy</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>